Illumina (NASDAQ:ILMN) had its price target boosted by investment analysts at Piper Jaffray Companies to $274.00 in a note issued to investors on Thursday. The brokerage currently has an “overweight” rating on the life sciences company’s stock. Piper Jaffray Companies’ target price suggests a potential upside of 20.09% from the company’s previous close.
Several other brokerages also recently commented on ILMN. Evercore ISI assumed coverage on shares of Illumina in a research note on Wednesday. They issued an “outperform” rating and a $250.00 price objective for the company. Wells Fargo & Co raised shares of Illumina from a “market perform” rating to an “outperform” rating and set a $205.00 price objective for the company in a research note on Tuesday, January 2nd. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, December 26th. Morgan Stanley increased their price objective on shares of Illumina from $122.00 to $135.00 and gave the company an “underweight” rating in a research note on Thursday, December 14th. Finally, Argus increased their price objective on shares of Illumina from $205.00 to $235.00 and gave the company a “buy” rating in a research note on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company. Illumina presently has an average rating of “Buy” and a consensus price target of $211.88.
Shares of Illumina (NASDAQ:ILMN) traded down $4.82 during trading on Thursday, hitting $228.17. 1,468,700 shares of the stock were exchanged, compared to its average volume of 842,922. Illumina has a 12 month low of $137.40 and a 12 month high of $233.54. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. The company has a market cap of $33,310.00, a P/E ratio of 43.05, a PEG ratio of 3.13 and a beta of 0.79.
In other news, Director Robert S. Epstein sold 1,250 shares of the firm’s stock in a transaction on Saturday, December 29th. The shares were sold at an average price of $217.38, for a total transaction of $271,725.00. Following the completion of the transaction, the director now owns 8,838 shares of the company’s stock, valued at $1,921,204.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Charles Dadswell sold 1,609 shares of the firm’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $207.88, for a total transaction of $334,478.92. Following the transaction, the senior vice president now directly owns 7,217 shares of the company’s stock, valued at approximately $1,500,269.96. The disclosure for this sale can be found here. Insiders have sold 158,921 shares of company stock valued at $33,810,181 in the last ninety days. Insiders own 0.89% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Advisory Services Network LLC increased its position in shares of Illumina by 13.0% during the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after buying an additional 89 shares during the period. Dupont Capital Management Corp acquired a new stake in shares of Illumina during the third quarter worth $153,000. Patten Group Inc. increased its position in shares of Illumina by 71.1% during the third quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock worth $172,000 after buying an additional 615 shares during the period. West Coast Financial LLC acquired a new stake in shares of Illumina during the third quarter worth $216,000. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Illumina during the second quarter worth $226,000. 91.60% of the stock is owned by hedge funds and other institutional investors.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
